Literature DB >> 10922055

Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA.

A Michienzi1, L Cagnon, I Bahner, J J Rossi.   

Abstract

The HIV regulatory proteins Tat and Rev have a nucleolar localization property in human cells. However, no functional role has been attributed to this localization. Recently it has been demonstrated that expression of Rev induces nucleolar relocalization of some protein factors involved in Rev export. Because the function of Rev is to bind HIV RNA and facilitate transport of singly spliced and unspliced RNA to the cytoplasm, it is likely that the nucleolus plays a critical role in HIV-1 RNA export. As a test for trafficking of HIV-1 RNAs into the nucleolus, a hammerhead ribozyme that specifically cleaves HIV-1 RNA was inserted into the body of the U16 small nucleolar RNA, resulting in accumulation of the ribozyme within the nucleoli of human cells. HeLa CD4(+) and T cells expressing this nucleolar localized ribozyme exhibit dramatically suppressed HIV-1 replication. The results presented here suggest a trafficking of HIV-1 RNA through the nucleoli of human cells, thus posing a different paradigm for lentiviral RNA processing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922055      PMCID: PMC16803          DOI: 10.1073/pnas.97.16.8955

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  58 in total

1.  Signal recognition particle components in the nucleolus.

Authors:  J C Politz; S Yarovoi; S M Kilroy; K Gowda; C Zwieb; T Pederson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

3.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

4.  rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA.

Authors:  B K Felber; M Hadzopoulou-Cladaras; C Cladaras; T Copeland; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

6.  Regulation of human immunodeficiency virus env expression by the rev gene product.

Authors:  M L Hammarskjöld; J Heimer; B Hammarskjöld; I Sangwan; L Albert; D Rekosh
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

8.  Subcellular localization of the human immunodeficiency virus trans-acting art gene product.

Authors:  B R Cullen; J Hauber; K Campbell; J G Sodroski; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

9.  The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs.

Authors:  D M D'Agostino; B K Felber; J E Harrison; G N Pavlakis
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

10.  Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors:  E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

View more
  55 in total

Review 1.  Small nucleolar RNAs: versatile trans-acting molecules of ancient evolutionary origin.

Authors:  Michael P Terns; Rebecca M Terns
Journal:  Gene Expr       Date:  2002

2.  A nucleolar TAR decoy inhibitor of HIV-1 replication.

Authors:  Alessandro Michienzi; Shirley Li; John A Zaia; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

3.  A biosensor for theophylline based on fluorescence detection of ligand-induced hammerhead ribozyme cleavage.

Authors:  Phillip T Sekella; David Rueda; Nils G Walter
Journal:  RNA       Date:  2002-10       Impact factor: 4.942

4.  Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo.

Authors:  Dirk Daelemans; Sylvain V Costes; Stephen Lockett; George N Pavlakis
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

Review 5.  The moving parts of the nucleolus.

Authors:  M O J Olson; Miroslav Dundr
Journal:  Histochem Cell Biol       Date:  2005-03-02       Impact factor: 4.304

6.  MicroRNA-206 colocalizes with ribosome-rich regions in both the nucleolus and cytoplasm of rat myogenic cells.

Authors:  Joan C Ritland Politz; Fan Zhang; Thoru Pederson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-29       Impact factor: 11.205

7.  Methodological obstacles in knocking down small noncoding RNAs.

Authors:  Andreas Ploner; Christian Ploner; Melanie Lukasser; Harald Niederegger; Alexander Hüttenhofer
Journal:  RNA       Date:  2009-08-18       Impact factor: 4.942

8.  Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.

Authors:  Hoshang J Unwalla; Haitang Li; Shi-Yang Li; Danny Abad; John J Rossi
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

9.  NC-mediated nucleolar localization of retroviral gag proteins.

Authors:  Timothy L Lochmann; Darrin V Bann; Eileen P Ryan; Andrea R Beyer; Annie Mao; Alan Cochrane; Leslie J Parent
Journal:  Virus Res       Date:  2012-10-02       Impact factor: 3.303

10.  Rev inhibition strongly affects intracellular distribution of human immunodeficiency virus type 1 RNAs.

Authors:  Dusan Cmarko; Stig-Ove Bøe; Catia Scassellati; Anne Marie Szilvay; Svend Davanger; Xiang-Dong Fu; Gunnar Haukenes; Karl-Henning Kalland; Stanislav Fakan
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.